ArriVent BioPharma
Market cap $553M 51.7M shares (10-Q, Nov 5, 2026) × $10.69 close Nov 17, 2026
Most recent annual filing: 2026-03-05
- WuXi AppTec / supply chainBy year-end 2026WuXi AppTec / supply chain, By year-end 2026, material
- ARR-217 Ph1 interim1H 2027ARR-217 Ph1 interim, 1H 2027, major
- firmonertinib readout1Q 2027firmonertinib readout, 1Q 2027, notable
- enozertinib ORIC trial start1H 2027enozertinib ORIC trial start, 1H 2027, routine
- zipalertinib PDUFA dateFeb 27, 2027zipalertinib PDUFA date, Feb 27, 2027, material
- ARR-217 + bevacizumab readout2H 2027ARR-217 + bevacizumab readout, 2H 2027, material
- ARR-217 + chemotherapy / PhaseYear-end 2027ARR-217 + chemotherapy / Phase, Year-end 2027, material
- firmonertinib ALPACCA readout~not guided; estimate ORR interim late 2027-late 2028, final PFS 2029-2030firmonertinib ALPACCA readout, ~not guided; estimate ORR interim late 2027-late 2028, final PFS 2029-2030, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (7 active programs)
ARR-002
AV-P138-ADCARR-217
MRG007ARR-421
ARR-173
Technology platforms
Alphamab ADC Platform · Jiangsu Alphamab Biopharmaceuticals
Alphamab's proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for oncology indications; ArriVent has exclusive rights to develop and commercialize ADCs globally except Greater China
Aarvik ADC Platform · Aarvik Pharmaceuticals
Research collaboration with Aarvik Pharmaceuticals to develop ADCs binding to two agreed targets; ArriVent holds exclusive option to license intellectual property generated under the collaboration
Aarvik Multi-Target Multivalent ADC Platform · Aarvik Therapeutics
Proprietary multi-target, multivalent, site-specific conjugation antibody platform for discovering next-generation ADCs with improved activity and safety over single target bivalent ADCs; focus on solid tumors / oncology indications globally
Alphamab Linker-Payload Glycan-Conjugation Platform · Alphamab
Proprietary linker-payload platform and glycan-conjugation technology for discovering novel ADCs; focus on oncology indications globally except greater China
MUTTA · Aarvik Therapeutics, Inc.
MUlti-epitope Targeting Tetravalent Antibody platform for developing next-generation ADCs with improved therapeutic window; focus on dual-target ADC approaches in oncology
Targets: MUC16, NaPi2b
Alphamab ADC Platform · Alphamab
Proprietary linker-payload platform and glycan-conjugation technology to identify novel antibody drug conjugates for oncology indications; ArriVent has exclusive rights to develop and commercialize ADCs globally except Greater China
Capital (as filed)
- Cash
- $114M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $280M Sep 30, 2026
- Operating cash flow
- −$40.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $393M cash, runway to mid-2028 per the deep dive of Nov 11, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (1)
- 2026-11-12 ArriVent BioPharma (AVBP) - Scientific Deep Dive for Firmonertinib, ARR-217 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (1 call)
Every verdict Biotech Distilled has published on ArriVent BioPharma, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-11-12 Watch ArriVent BioPharma (AVBP) - Scientific Deep Dive for Firmonertinib, ARR-217 and Pipeline Products At ~$306M EV the stock is roughly fairly priced for two binary assets with no dated readout on the lead; FURVENT missed on a comparator anomaly rather than drug failure, but ALPACCA faces the same measurement risk against stronger comparators and ARR-217's confirmed response rate needs validation in a larger, more mature cohort.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“In January 2025, Taiho Therapeutics and Cullinan Therapeutics announced that their study of the oral EGFR inhibitor zipalertinib met the primary endpoint in a Phase 2b clinical trial of patients in second or later line NSCLC patients with EGFR exon 20 insertion mutations and in April 2026 announced a February 27, 2027 Prescription Drug User Fee Act (“PDUFA”) target action date for the New Drug Application (“NDA”) filed for that indication.”
matched to zipalertinib · regulatory decision
-
-
-
“We plan to provide an update on firmonertinib in the first quarter of 2027 around the review of the FURVENT study. · Phase 1b Data for ARR-217.”
matched to firmonertinib · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (19)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 20268-KCurrent report: results of operations, officer / director change · EX-99.1 EXHIBIT 99.1
- Nov 9, 202610-QQuarterly report
- Oct 26, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Oct 19, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Oct 13, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Oct 8, 2026SCHEDULE 13D/A13D amendment
- Oct 6, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Aug 12, 20268-KCurrent report: material agreement, results of operations · EX-99.1 EXHIBIT 99.1
- Aug 12, 202610-QQuarterly report
- Jun 22, 20268-KCurrent report: shareholder vote
- May 11, 20268-KCurrent report: other events
- May 11, 20268-KCurrent report: results of operations · EX-99.1
- May 11, 2026424B5Prospectus supplement (offering)
- May 11, 202610-QQuarterly report
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Mar 17, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Mar 5, 20268-KCurrent report: results of operations · EX-99.1
- Mar 5, 202610-KAnnual report
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Oct 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 27, 2026SCHEDULE 13G/A13G amendment
- May 6, 2026SCHEDULE 13G/A13G amendment
- Apr 28, 2026ARSAnnual report to shareholders
- Mar 5, 2026SCHEDULE 13G/A13G amendment
- Mar 5, 2026S-8Employee plan registration